- Conditions
- Healthy
- Interventions
- Moderately-high dose of psilocybin, Moderately-low dose of psilocybin, Very-low dose of psilocybin, Placebo
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 25 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 889–912
of 2,377
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Low Grade Endometrioid Adenocarcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Ovarian Low Grade Endometrioid Adenocarcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma
- Interventions
- BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Tuvusertib, X-Ray Imaging
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 14
- States / cities
- Augusta, Georgia • Chicago, Illinois • Iowa City, Iowa + 8 more
- Conditions
- Repetitive Negative Thinking, Serious Mental Illness Symptoms
- Interventions
- Mindfulness Training, Active mindfulness-based neurofeedback (Active mbNF), Sham mindfulness-based neurofeedback
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 14 Years to 21 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
- Interventions
- Computed Tomography, Fludeoxyglucose F-18, Laboratory Biomarker Analysis, Positron Emission Tomography, Radiation Therapy, Single Photon Emission Computed Tomography, Technetium Tc-99m Albumin Aggregated, Technetium Tc-99m Sulfur Colloid
- Procedure · Radiation · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 2
- States / cities
- Seattle, Washington
- Conditions
- Fallopian Tube Carcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Ovarian Carcinoma, Ovarian High Grade Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Carcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Cediranib Maleate, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Olaparib, Questionnaire Administration
- Procedure · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 12 more
- Conditions
- Body Dysmorphic Disorder
- Interventions
- PET scan and MRI scan
- Procedure
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Sickle Cell Disease
- Interventions
- Positron Emission Tomography, Cu-64]-LLP2A
- Radiation · Drug
- Lead sponsor
- Enrico Novelli
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Grade III or Grade IV Glioma
- Interventions
- PET imaging with 18F fluciclovine
- Drug
- Lead sponsor
- Nicole Hill
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Lenalidomide, Magnetic Resonance Imaging, Obinutuzumab, Positron Emission Tomography, Prednisone, Venetoclax
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 115
- States / cities
- Tucson, Arizona • Los Angeles, California • Derby, Connecticut + 94 more
- Conditions
- Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm
- Interventions
- Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody, Biopsy, Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Quality-of-Life Assessment, Siltuximab
- Biological · Procedure · Other
- Lead sponsor
- Yuanquan Yang
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Hepatocellular Carcinoma
- Interventions
- MRI Scan of the Liver enhanced with Eovist
- Procedure
- Lead sponsor
- San Francisco Veterans Affairs Medical Center
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Sciatica
- Interventions
- Radioactive dye, PET/MRI, Blood draw
- Drug · Radiation · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Physical Activity
- Interventions
- Isometric Contraction Exercise - Young Adults (Age group 18-39), Isometric Contraction Exercise - Middle Age Adults (Age group 40-59), Isometric Contraction Exercise - Old Adults (Age group >60)
- Other
- Lead sponsor
- Pennington Biomedical Research Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 352 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- bleomycin, Ommaya reservoir, radiation therapy
- Biological · Device · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Lexington, Kentucky • Omaha, Nebraska + 10 more
- Conditions
- Brain Tumor, Recurrent, Adult
- Interventions
- PET/CT with F-Fluciclovine (Axumin)
- Drug
- Lead sponsor
- Loma Linda University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Loma Linda, California
- Conditions
- Non-alcoholic Fatty Liver Disease
- Interventions
- Magnetic Resonance Imaging (MRI)
- Procedure
- Lead sponsor
- Emory University
- Other
- Eligibility
- 7 Years to 18 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Alzheimer Disease, Alzheimer Dementia, Frontotemporal Dementia
- Interventions
- Spectral-Domain Optical Coherence Tomography (SD-OCT), Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Comprehensive Ophthalmic Examination, Fundus Photography
- Device · Diagnostic Test
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 45 Years to 80 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Esophageal Diseases
- Interventions
- CEI Thoracic Surgical Implantation-Cellspan™ Esophageal Implant-Adult (CEI) in patients requiring a full reconstruction of the esophagus, CEI Extra-Thoracic Subdermal Surgical Implantation - Cellspan™ Esophageal Implant-Adult (CEI) in patients that have had a previous partial esophagectomy
- Combination Product
- Lead sponsor
- Harvard Apparatus Regenerative Technology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Ann Arbor, Michigan • Rochester, Minnesota
- Conditions
- Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
- Interventions
- Computed Tomography, Fludeoxyglucose F-18, Medical Device Usage and Evaluation, Positron Emission Tomography
- Procedure · Other · Device
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
- Interventions
- 89Zr-DFO-YS5, YS5 antibody, Positron Emission Tomography (PET)/Computerized tomography (CT), Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI)
- Drug · Biological · Procedure
- Lead sponsor
- Robert Flavell, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Localized Prostate Carcinoma, Oligometastatic Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Interventions
- Bilateral Pelvic Lymph Node Dissection, Biospecimen Collection, Bone Scan, Computed Tomography, Electronic Health Record Review, Flotufolastat F-18 Gallium, Laparoscopic Radical Prostatectomy with Robotics, Magnetic Resonance Imaging, Positron Emission Tomography
- Procedure · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 30 Years to 85 Years · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Breast Cancer
- Interventions
- laboratory biomarker analysis, needle biopsy, positron emission tomography, radionuclide imaging, fludeoxyglucose F 18
- Other · Procedure · Radiation
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 2
- States / cities
- Seattle, Washington
- Conditions
- Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Colorectal Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Pancreatic Adenocarcinoma
- Interventions
- Biospecimen Collection, Computed Tomography, Electronic Health Record Review, Medical Device Usage and Evaluation, Physical Performance Testing, Positron Emission Tomography, Survey Administration
- Procedure · Other
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 225
- States / cities
- Fort Smith, Arkansas • Aurora, Colorado • Boulder, Colorado + 160 more
- Conditions
- Neuroendocrine Tumors, Well-Differentiated Neuroendocrine Carcinoma, High Grade Neuroendocrine Carcinoma, Any Site
- Interventions
- Lenvatinib, Pembrolizumab, Hyperpolarized 13C-Pyruvate
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- San Francisco, California